Leaf

Waylivra

The only therapy licensed to treat FCS, as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate (1)

Waylivra

The only therapy licensed to treat FCS, as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate (1)

Balancing the challenges of FCS
 

Living with FCS is a daily challenge

Waylivra is the only therapy licensed to treat FCS, as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate1

Waylivra is an antisense oligonucleotide designed to inhibit the formation of apoC-III1

After 3 months, when added to diet, Waylivra delivered a 77% mean reduction fasting tryglyceride percentage change vs placebo which had a increase of 18 % from baseline1

With proactive monitoring, Waylivra has a safety profile that can be managed1

References

  1. Waylivra® SmPC